Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - A clinicopathological study

Leukemia

Volumn 13, Issue 11, 1999, Pages 1741-1748

  Thiele, J ^a   Kvasnicka, H M ^b   Boeltken, B ^b   Zankovich, R ^b   Diehl, V ^b   Fischer, R ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b NONE

Author keywords

Bone marrow biopsies; Fiber density; Histopathology; Idiopathic (primary) myelofibrosis; Megakaryopoiesis; Prefibrotic stages

Indexed keywords

ADIPOSE TISSUE; ADULT; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SHAPE; CYTOLOGY; DISEASE COURSE; DYSPLASIA; ERYTHROPOIESIS; FEMALE; FOLLOW UP; GRANULOCYTE; HEMATOPOIESIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MYELOFIBROSIS; NEUTROPHIL; PRIORITY JOURNAL; SPLENOMEGALY; SYMPTOM; THROMBOCYTOSIS;

EID: 0032697583     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401553     Document Type: Article

References (40)

1. Geary CG. Clinical and hematological aspects of chronic myelofibrosis. In: Lewis SM (ed.). Myelofibrosis, Pathophysiology and Clinical Management. Marcel Dekker, New York, 1985, pp 15-49.
2. Varki A, Lottenberg R, Griffith R, Reinhard E. The syndrome of idiopathic myelofibrosis: a cliniopathologic review with emphasis on the prognostic variables predicting survival. Medicine 1983; 62: 353-371.
3. Barosi G, Berzuini C, Liberator LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1988; 70: 397-401.
4. Smith RE, Chelmowski MK, Szabo EJ. Myelofibrosis: a concise review of clinical and pathologic features and treatment. Am J Hematol 1988; 29: 174-180.
5. Wolf BC, Neimann RS. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 1985; 65: 803-809.
6. Anger B, Seidler R, Haug U, Popp C, Heimpel H. Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica 1990; 75: 228-234.
7. Visani G, Finelli C, Castelli U, Petti MC, Ricci P, Vianelli N, Gianni L, Zuffa E, Aloe Spiriti MA, Lalagliata R, Pileri S, Magrini U, Gugliotta L, Morra E. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patient. Br J Haematol 1990; 75: 4-9.
8. Pereira A, Cervantes F, Brugues R, Rozman C. Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation. Eur J Haematol 1990; 44: 94-98.
9. Rozman C, Giralt M, Feliu R, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991; 67: 2658-2663.
10. Rupoli S, Da Lio L, Sisti S, Campanati G, Salvi A, Brianzoni MF, D'Amico S, Cinciripini A, Leoni P. Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. Ann Hematol 1994; 68: 205-212.
11. Tefferi A, Siverstein MN, Noël P. Agnogenic myeloid metaplasia. Semin Oncol 1995; 22: 327-333.
12. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F. Prognostic factors of agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-1018.
13. Cervantes F, Pereira A, Esteve J. Rafel M, Cobo F, Rozman C, Montserrat E. Identification of 'short-lived' and 'long-lived' patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97: 635-640.
14. Reilly JT, Snowdon JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, Potter A. Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997; 98: 96-102.
15. Cervantes F, Barosi G, Demory JL, Reilly J, Guarnone R, Dupriez B, Pereira A, Montserrat E. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102: 684-690.
16. Hasselbach H. Idiopathic myelofibrosis - an update with particular reference to clinical aspects and prognosis. Int J Clin Lab Res 1993; 23: 124-138.
17. Hasselbach H, Lisse I. A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis. Eur J Haematol 1991; 46: 285-289.
18. Lohmann TB, Beckman EN. Progressive myelofibrosis in agnogenic myeloid metaplasia. Arch Pathol Lab 1983; 107: 593-594.
19. Thiele J, Chen YS, Kvasnicka HM, Diehl V, Fischer R. Evolution of fibro-osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis - a histomorphometric study on sequential trephine biopsies. Leuk Lymphoma 1994; 14: 163-169.
20. Charbord P, Neel H, Caillou B, Kahn E, Paremntier C. Effect of alkylating agents on hematopoiesis in myelofibrosis. Nouv Rev Fr d'Hématol 1984; 26: 361-369.
21. Manoharan A, Pitney WR. Chemotherapy resolves symptoms and reverses fibrosis in myelofibrosis. Scand J Haematol 1984; 33: 453-459.
22. Löfvenberg E, Wahlin A, Ross G, Öst A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990; 44: 33-38.
23. Sacchi S. The role of α-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update. Leuk Lymphoma 1995; 19: 13-20.
24. Thiele J, Simon KG, Fischer R, Zankovich R. Follow-up studies with sequential bone marrow biopsies in chronic myeloid leukemia and so-called primary (idiopathic) osteo-myelofibrosis. Evolution of histopathological lesions and clinical courses in 40 patients. Pathol Res Pract 1988; 183: 434-445.
25. Buhr T, Georgii A, Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Path Res Pract 1993; 189: 121-132.
26. Georgii A, Buhr T, Buesche G, Kreft A, Choritz H. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma 1996; 22 (Suppl. I): 15-29.
27. Georgii A, Vykoupil KF, Buhr T, Choritz H, Döhler U, Kaloutsi V, Werner M. Chronic myeloproliferative disorders in bone marrow biopsies. Path Res Pract 1990; 186: 3-27.
28. Jamshidi K, Swaim WR. Bone marrow biopsy with unaltered architecture: a new biopsy device. J Lab Clin Med 1971; 77: 335-342.
29. Schaefer HE. How to fix, decalcify and stain paraffin embedded bone marrow biopsies. In: K Lennert, K Huebner G (eds). Pathology of the Bone Marrow. Fischer: Stuttgart, 1998, pp 6-9.
30. Gatter KC, Cordell JL, Turley H, Heryet A, Kiefer N, Anstee DJ, Mason DJ. The immunohistological detection of platelet, megakaryocytes and thrombi in routinely processed specimens. Histopathology 1988; 13: 257-267.
31. Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol 1995; 22: 355-373.
32. Cervantes F, Pereia A, Esteve J, Cobo F, Rozman C, Montserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 1998; 60: 101-105.
33. Thiele J, Kvasnicka HM, Diehl V, Fischer, Michiels JJ. Clinicopathological diagnosis and differential criteria of thrombocythemias in various myeloproliferative disorders by histopathology, histochemistry and immunostaining from bone marrow biopsies. Leuk Lymphoma 1998; 33: 207-218.
34. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39.
35. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemostas 1997; 23: 229-347.
36. Kvasnicka HM, Thiele J, Werden C, Zankovich R, Diehl V, Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 1997; 15: 708-719.
37. Thiele J, Hoeppner B, Zankovich R, Fischer R. Histomorphometry of bone marrow biopsies in primary osteomyelofibrosis/-sclerosis (agnogenic myeloid metaplasia) - correlations between clinical and morphological features. Virch Arch A Pathol Anat Histol 1989; 514: 191-202.
38. Apaja-Sarkinnen M, Autio-Harmainen H, Alavaikko M, Risteli L. Immunohistochemical study of basement membrane proteins and type III procollagen in myelofibrosis. Br J Haematol 1986; 63: 571-580.
39. Reilly JT. Pathogenesis of idiopathic myelofibrosis: role of growth factors. J Clin Pathol 1992; 45: 461-464.
40. Martyré MC. TGF-β and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders. Leuk Lymphoma 1995; 20: 39-44.